Smith & Nephew/$SNN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.
- Ticker
- $SNN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 17,000
- Headquarters
- Watford, United Kingdom
- Website
- www.smith-nephew.com
Smith & Nephew Metrics
BasicAdvanced
$12B
41.12
$0.74
0.69
$0.75
3.09%
Price and volume
Market cap
$12B
Beta
0.69
52-week high
$37.09
52-week low
$26.12
Average daily volume
1.2M
Dividend rate
$0.75
Financial strength
Current ratio
2.139
Quick ratio
1.109
Long term debt to equity
0.62
Total debt to equity
0.731
Dividend payout ratio (TTM)
52.44%
Interest coverage (TTM)
6.59%
Profitability
EBITDA (TTM)
1,382
Gross margin (TTM)
68.44%
Net profit margin (TTM)
10.08%
Operating margin (TTM)
14.22%
Effective tax rate (TTM)
20.33%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
5.16%
Return on equity (TTM)
11.85%
Valuation
Price to earnings (TTM)
41.115
Price to revenue (TTM)
4.105
Price to book
1.82
Price to tangible book (TTM)
11.26
Price to free cash flow (TTM)
30.249
Free cash flow yield (TTM)
3.31%
Free cash flow per share (TTM)
1
Dividend yield (TTM)
2.49%
Forward dividend yield
3.09%
Growth
Revenue change (TTM)
5.99%
Earnings per share change (TTM)
31.78%
3-year revenue growth (CAGR)
5.61%
10-year revenue growth (CAGR)
3.00%
3-year earnings per share growth (CAGR)
43.34%
10-year earnings per share growth (CAGR)
6.37%
3-year dividend per share growth (CAGR)
1.92%
10-year dividend per share growth (CAGR)
2.41%
What the Analysts think about Smith & Nephew
Analyst ratings (Buy, Hold, Sell) for Smith & Nephew stock.
Analyst projections of the future price of Smith & Nephew stock.
Bulls say / Bears say
H1 trading profit rose 8.1%, adjusted EPS rose 11% and the margin expanded by 60 basis points. The company kept its profit and cash-flow targets despite lowering its sales outlook, as efficiency savings helped protect earnings. (Smith+Nephew)
Sports Medicine remains a growth engine: the company reported continued strength and double-digit growth across several platforms, including REGENETEN and FASTSEAL. New launches and broader clinical approvals could extend that momentum, although adoption remains to be proven. (Smith+Nephew)
Shareholder returns are supported by cash generation and a relatively modest 1.8x net debt-to-EBITDA ratio. The company announced a $500 million buyback and raised its interim dividend by 4%. (Smith+Nephew)
Sales momentum has weakened: after second-quarter underlying growth of 1.6%, Smith+Nephew cut its 2026 growth forecast to around 4% from around 6%. US knee implant revenue fell 7.2% in the quarter, leaving the recovery dependent on new products and better demand. (Reuters, Smith+Nephew)
Advanced Wound Bioactives faces reimbursement pressure: its revenue fell 12.7% in the second quarter, and the company expects the skin-substitute profit headwind to be near the top of its $20–40 million range. A return to growth in SANTYL and stabilisation in skin substitutes are not yet assured. (Smith+Nephew)
The longer-term growth case is also in question. Morgan Stanley said the 2025–28 revenue target looked ambitious and may need rebasing given challenges in Orthopaedics, Wound Bioactives and China. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 31 Oct 2026.
Smith & Nephew Financial Performance
Revenues and expenses
Smith & Nephew Earnings Performance
Company profitability
Upcoming events
Smith & Nephew News
AllArticlesVideos
Funds containing Smith & Nephew
AllGBPEURUSD
Fund name | Fund size | $SNN weighting |
|---|---|---|
Vanguard FTSE 100£VUKE | £4.7B | 0.33% |
Vanguard FTSE 100£VUKG | £1.9B | 0.33% |
Vanguard ESG Developed Europe All Cap£V3EA | €125M | 0.11% |
Vanguard ESG Developed Europe All Cap£V3EL | €35M | 0.11% |
Vanguard FTSE Developed Europe€VWCG | €2.9B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.